Exelixis, Inc. Announces Third Quarter 2013 Financial Results

Published: Oct 31, 2013

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the quarter ended September 30, 2013.

Q3 2013 Highlights and Recent Events

•Reported net product revenue for COMETRIQ® (cabozantinib) of $4.8 million in the third quarter of 2013.

•Reached the enrollment target of 960 patients for COMET-1, the phase 3 pivotal trial of cabozantinib in patients with metastatic castration-resistant prostate cancer (mCRPC). The primary endpoint of COMET-1 is overall survival (OS).

Help employers find you! Check out all the jobs and post your resume.

Back to news